Merck, 90110506-1VL, 45.6.TG1.7

Application
Fusion partner, immunoglobulin production
Biochem/physiol Actions
Derived from a female BALB/c myeloma tumour MPC-11. The parental cell line has mutated during growth in 6-thioguanine to establish the drug resistant line 45.6.TG1.7. This line is HPRT negative and produces mouse IgG2b kappa immunoglobulins.
Mouse BALB/c myeloma
Preparation Note
DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Maintain cultures between 4-5x100,000 cells/ml; 5% CO₂; 37°C. Cells achieve a maximum cell density of 1-1.5x1,000,000 cells/ml.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].